Eli Lilly’s obesity and diabetes treatments fuel growth and spark bidding war

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...

Eli Lilly raises forecasts on surging demand for weight-loss drugs

Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong appetite for its widely popular weight-loss ...

Eli Lilly partners with Walmart to sell weight loss drug directly to patients nationwide

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...
Fierce Pharma

Lilly's Zepbound, Mounjaro show out with $10B quarter despite CVS formulary hitch

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...
Fierce Healthcare

Eli Lilly, Walmart launch retail pick-up option for weight loss drug Zepbound

Pharma giant Eli Lilly tapped Walmart to offer in-store pickups of Zepbound vials, marking the first retail collaboration for ...
BioSpace

Zepbound Topples Sales King Keytruda as Lilly Reports 54% YoY Revenue Rise for Q3

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...

Eli Lilly Boosts Its Outlook on High Demand for Popular Weight-Loss Drugs

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

Lilly aligns with Walmart in bid to broaden access to discounted Zepbound

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...